ISCHEMAVIEW
15.5.2018 07:02:10 CEST | Business Wire | Press release
Today at the European Stroke Organization Conference, iSchemaView, the leader in automated cerebrovascular imaging analysis, publicly launched RAPID ASPECTS, a digital imaging solution that assists clinicians in assessing early signs of brain ischemia in stroke. RAPID ASPECTS automatically generates a standardized score — based on clinically validated machine learning algorithms — that enables physicians to easily communicate about the extent of a patient’s ischemic changes and to determine eligibility for thrombectomy (clot removal). In addition, RAPID ASPECTS provides clear visualization of the brain so that clinicians can better scrutinize each region and confirm the automated score. RAPID ASPECTS is CE-marked for use in Europe.
The original Alberta Stroke Program Early CT Score (ASPECTS) is a manual 10-point scoring system that relies on determining subtle changes in non-contrast CT examinations. This has traditionally required the expertise of an experienced neuroradiologist or stroke neurologist. Yet even stroke imaging experts have been shown to display significant scoring variability in most studies using ASPECTS . RAPID ASPECTS automates and standardizes the scoring process to help clinicians more accurately assess early signs of brain ischemia.
“In my opinion, using RAPID ASPECTS increases the likelihood of getting a reliable ASPECT score, independent of the individual skills and experience of the clinician. This tool is therefore particularly suitable for primary stroke centers with a smaller number of cases,” said Dr. Benjamin Friedrich, docent and physician in the Department of Diagnostic and Interventional Neuroradiology at the Klinikum rechts der Isar in Munich. “Early and reliable information makes it possible to quickly understand the prognosis of a patient.”
“ASPECT scoring plays a critical role in the treatment of brain ischemia leading to stroke and is part of the American Heart Association guidelines for use of endovascular therapy in patients who can be treated within six hours of symptom onset,” said Greg Albers, Professor of Neurology at Stanford University, Director of the Stanford Stroke Center and cofounder of iSchemaView. “RAPID ASPECTS elevates the ASPECT scoring system, by providing clinicians with more reliable and reproducible scores and powerful visualization tools to support treatment decisions.”
RAPID ASPECTS receives data from standard CT scanners, tilt-corrects the images and identifies the ASPECTS regions. A sliding confidence indicator allows the physician to scrutinize suspicious regions and determine a final score. Moving the confidence slider to the left identifies additional regions that may potentially be involved, while moving the slider to the right removes regions with more subtle differences. In addition, RAPID ASPECTS includes these features:
- Slice up and down, zoom and window options that enable the clinician to evaluate different regions of interest
- Manual score adjustment by adding or subtracting regions
- Return to fully automated score with one click
“RAPID ASPECTS is the state-of-the-art offering for consistent, actionable ASPECT scoring,” said Don Listwin, CEO of iSchemaView. “Clinicians who use RAPID ASPECTS are better able to facilitate quick diagnoses and share information with internal care teams or specialty treatment centers for referrals. Whether it’s CTP, CTA, MRI or now ASPECTS, more than four hundred stroke centers worldwide are using RAPID imaging solutions to successfully identify and treat more stroke patients than ever before.”
Key Presentations at ESOC
iSchemaView cofounder, Dr. Greg Albers, will present at three sessions:
- “Key Subgroup Analyses From the DEFUSE 3 Study ” during the Presidential Symposium on Wednesday, May 16 at 15:00 in Hall C.
- “Validation of the Clinical/Core Mismatch and Perfusion/Core Mismatch Selection Criteria for Late Window Thrombectomy: Pooled Analysis of DEFUSE 3 And DAWN ” during the Reperfusion II session on Thursday, May 17 at 10:40 in Hall K3.
- Medtronic Care Continuum: Patient Pathway , Thursday, May 17, at 12:45 in Hall K1.
Dr. Benjamin Friedrich of the Department of diagnostic and interventional Neuroradiology at the Klinikum rechts der Isar will present a paper on automated ASPECTS scoring software, titled “Software-Based, Automated Calculation of the ASPECT Score In Patients Suffering From Emergent Vessel Occlusions in the Anterior Circulation – Clinical Feasibility And Reliability ,” during the Reperfusion Trials session on Friday, May 18 at 09:50 in Hall K2.
About iSchemaView
iSchemaView is the leader in cerebrovascular imaging analysis, delivering the proven software tools that healthcare professionals around the world use to successfully identify and treat more stroke patients than ever before. iSchemaView’s RAPID is the most advanced brain imaging platform, and in clinical trials, under IRB, RAPID has been shown to aid in the selection of patients in early and late window stroke trials, including SWIFT PRIME, EXTEND IA, DAWN and DEFUSE 3. In addition to achieving the best clinical outcomes and largest treatment effects ever obtained, these landmark studies led to new American Heart Association and American Stroke Association guidelines and have dramatically altered the management of acute stroke around the world. For more information, visit www.iRAPID.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20180514006439/en/
Contact:
for iSchemaView
Peter Evers, 415-888-3314
Natron Communications
peter@natroncomm.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Current Chemicals Expands U.S. Production of Rare-Earth Fluorides With New Investment From Momentum Global Ventures5.11.2026 14:14:00 CET | Press release
Current Chemicals receives additional capital to scale U.S. capacity for critical rare-earth fluorides used in magnets, advanced coatings, and alloys Current Chemicals, Inc. (“CCI”), one of the few U.S. companies converting separated rare-earth oxides into the fluorides used to make rare-earth metals and magnets, today announced an additional investment from its lead shareholder, Momentum Global Ventures (“MGV”). The investment will significantly increase CCI’s production of neodymium fluoride, dysprosium fluoride, and other key rare-earth fluorides in Cleveland. The funding adds infrastructure, equipment and engineering staff for fluorides of neodymium, dysprosium, terbium, gadolinium, yttrium, scandium, lanthanum, and lithium for reducing light rare-earths to metal: key inputs for permanent magnets, advanced coatings, and alloys. Neodymium fluoride and dysprosium fluoride are key feedstocks for the metal at the core of high-performance magnets in electric motors, wind turbines and de
iConnections and Preqin, a Part of BlackRock, Announce Collaboration to Bring Institutional Data to Violet, an AI-Powered Capital Introduction Platform5.11.2026 14:00:00 CET | Press release
Preqin's private markets data will be available inside Violet, iConnections' AI-powered capital introduction platform, to help drive networking and greater discovery for attendees of iConnections' Global Alts events iConnections today announced a collaboration with Preqin, a part of BlackRock, that brings one of the industry's leading sources of private markets data and intelligence— spanning fund managers, institutional investors, funds, benchmarks and indices— to Violet, iConnections' AI-powered capital introduction platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105840622/en/ Preqin's data is now inside Violet Powered by Preqin, the integration gives Global Alts attendees access to a broader network of institutional alternatives market participants, inside the same platform where thousands of allocators and managers already discover one another, book meetings and build relationships. “Alternative investing has
SLB OneSubsea Awarded Contract for Lyra Field Development Offshore Norway5.11.2026 13:49:00 CET | Press release
Close collaboration and standardized subsea technology accelerate path to first production Global energy technology company SLB (NYSE: SLB) today announced that its OneSubsea™ joint venture has been awarded a contract by Aker BP to deliver subsea production systems, umbilicals and associated services for the Lyra field development, formerly known as Kjøttkake, on the Norwegian Continental Shelf (NCS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104799196/en/ The SLB (NYSE: SLB) OneSubsea™ joint venture has been awarded a contract by Aker BP to deliver subsea production systems, umbilicals and associated services for the Lyra field development, formerly known as Kjøttkake, on the Norwegian Continental Shelf (NCS). Building on nearly a decade of collaboration through Aker BP’s alliance model, Aker BP and SLB OneSubsea worked together from the early stages of the project to shape the development strategy for Lyra. The fie
EURONAVAL 2026: Naval Group and Technology Innovation Institute (TII) Sign an Agreement to Pool Their Expertise in Advanced Autonomous Underwater Technologies.5.11.2026 12:48:00 CET | Press release
Signed on 3rd November 2026, the agreement brings together TII’s expertise in autonomous systems and Naval Group’s expertise in naval autonomous systems design, development and integration to explore the development and commercialization of advanced autonomous underwater solutions. The Technology Innovation Institute, the applied-research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), has signed an agreement with Naval Group, a global leader in naval defense, to advance cooperation in autonomous underwater technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105684133/en/ EURONAVAL 2026: Naval Group and Technology Innovation Institute (TII) sign an agreement to pool their expertise in advanced autonomous underwater technologies. (Photo: AETOSWire) Announced during Euronaval 2026, the collaboration will focus on exploring opportunities for the joint development and commercialization of uncrewed
BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates5.11.2026 12:00:00 CET | Press release
Total global revenues of $1.9 billion for the third quarter, an increase of 34% from the prior yearBRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter, an increase of 34% from the prior yearDiluted GAAP Earnings per American Depository Share (ADS) of $3.28 for the third quarter; non-GAAP diluted Earnings per ADS of $4.59 for the third quarterRaised 2026 total revenue guidance to $6.9 to $7.0 billion; GAAP operating income of $1.2 to $1.3 billion, non-GAAP operating income of $1.9 to $2.0 billion BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in pat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
